Exopharm Limited (ASX:EX1) shares were down 1.3% on Thursday . The company traded as low as A$0.39 ($0.28) and last traded at A$0.40 ($0.28), approximately 32,500 shares were traded during trading. The stock had previously closed at A$0.40 ($0.28).
The company has a market capitalization of $37.67 million and a price-to-earnings ratio of -9.88.
In other Exopharm news, insider Jason Watson 100,000 shares of Exopharm stock in a transaction that occurred on Friday, September 13th.
About Exopharm (ASX:EX1)
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing clinical human therapeutics in Australia. It is developing Plexaris, an exosome derived from human platelets; and Exomeres, an exosome derived from adult stem cells. The company was founded in 2003 and is headquartered in Melbourne, Australia.
Featured Article: What does a market perform rating mean?
Receive News & Ratings for Exopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exopharm and related companies with MarketBeat.com's FREE daily email newsletter.